Tower Research Capital (TRC)’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

Tower Research Capital (TRC)’s Portfolio CLCD Stock Details CLCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,571	Closed	-$57K	–	4560
2016 Q4	$57K	Buy	+1,571	New	+$55.6K	0.01%	1353
2016 Q2	–	Sell	-1,339	Closed	-$8K	–	5413
2016 Q1	$8K	Buy	1,339 +539	+67%	+$3.37K	﹤0.01%	2299
2015 Q4	$7K	Sell	800 -10,755	-93%	-$56.6K	﹤0.01%	2685
2015 Q3	$45K	Buy	+11,555	New	+$85.4K	﹤0.01%	1106

Other funds holding CLCD

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Tower Research Capital (TRC)'s CLCD Position: Q1 2017 in Review

Tower Research Capital (TRC) sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q1 2017, closing a stake of 1,571 shares — an estimated $57K sold.

Tower Research Capital (TRC) first reported a position in CLCD in Q3 2015 and held it in 4 quarters. The position peaked at $57K in Q4 2016. 1 fund tracked by Wall St. Rank holds CLCD as of Q1 2017.

Tower Research Capital (TRC) reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Tower Research Capital (TRC) sold 1,571 CoLucid Pharmaceuticals, Inc. shares in Q1 2017, an estimated $57K.
Tower Research Capital (TRC) first reported a position in CoLucid Pharmaceuticals, Inc. in Q3 2015 and held it in 4 quarters.
Tower Research Capital (TRC)'s CoLucid Pharmaceuticals, Inc. position peaked at $57K in Q4 2016.
1 fund tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q1 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2017, filed 19 May 2017.